Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) will participate in a fireside chat at the Jefferies London Healthcare Conference on November 17, 2022, at 2:40 p.m. GMT / 9:40 a.m. ET. A live webcast and an archived recording will be available on their Investor Relations website for 90 days following the event. The company focuses on innovative biopharmaceutical solutions, with its lead candidate, LUMRYZ™, aimed at treating narcolepsy. Further details can be found on Avadel's website.

News Market Reaction – AVDL

+8.20%

+8.20% Session move

In the trading session that priced this news, AVDL gained 8.20%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 17 at 2:40 p.m. GMT / 9:40 a.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ™, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688

FAQ

When is Avadel Pharmaceuticals' fireside chat at the Jefferies London Healthcare Conference?

Avadel Pharmaceuticals' fireside chat is scheduled for November 17, 2022, at 2:40 p.m. GMT / 9:40 a.m. ET.

How can I access the webcast of Avadel Pharmaceuticals' conference participation?

The webcast of Avadel Pharmaceuticals' participation will be available live and archived on their Investor Relations website for 90 days after the conference.

What is the focus of Avadel Pharmaceuticals?

Avadel Pharmaceuticals focuses on transforming medicines, with an emphasis on innovative solutions for the treatment of narcolepsy.

What is LUMRYZ™ developed by Avadel Pharmaceuticals?

LUMRYZ™ is an investigational formulation of sodium oxybate designed for once-daily use at bedtime to treat narcolepsy symptoms.

What is the stock symbol for Avadel Pharmaceuticals?

The stock symbol for Avadel Pharmaceuticals is AVDL.